| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 01/13/2004 | US6677372 N-(3-benzofuranyl)urea-derivatives |
| 01/13/2004 | US6677370 Stabilizing microtubules and preventing depolymerization; antiproliferative, anticarcinogenic and antiinflammatory agents; autoimmune diseases |
| 01/13/2004 | US6677368 4-aryl substituted indolinones |
| 01/13/2004 | US6677357 Nerve growth factor; animal growth regulator; antitmor agent |
| 01/13/2004 | US6677355 Hydroxamic acid compounds useful as matrix metalloproteinase inhibitors |
| 01/13/2004 | US6677354 Treating sleep, brain, sexual, cardiovascular, nervous system, psychological, glandular, and gastrointestinal disorders |
| 01/13/2004 | US6677352 Non-insulin dependent, latent autoimmune, gestational diabetes treatment; impaired glucose tolerance; obesity, hypotensive agents |
| 01/13/2004 | US6677351 Useful in treatment of asthma and inflammation |
| 01/13/2004 | US6677345 Cyclin dependent kinase inhibitors |
| 01/13/2004 | US6677340 Gonadotropin-releasing hormone receptor antagonists and methods relating thereto |
| 01/13/2004 | US6677334 Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof |
| 01/13/2004 | US6677319 Phosphatidylcholine as medication with protective effect large intestinal mucosa |
| 01/13/2004 | US6677309 Anthracycline derivatives |
| 01/13/2004 | US6677308 Integrin antagonists; antitumor, antimetastasis, anticarcinogenic agents; angiogenesis and restenosis inhibitors; osteoporosis |
| 01/13/2004 | US6677301 Epithelial cell proliferation stimulants; wound healing agents |
| 01/13/2004 | US6677116 Methods for treating cancer by modulating β-catenin mediated gene expression |
| 01/13/2004 | US6676971 Crosslinked macromolecules |
| 01/13/2004 | US6676941 For inhibiting angiogenesis and induce tumor regression; cancer therapy |
| 01/13/2004 | US6676939 Methods of modulating IL-174 response |
| 01/13/2004 | US6676934 Antitumor agents; prevent or suppress glucose uptake; disrupt microtubules; induce apoptosis |
| 01/13/2004 | US6676924 CDR-grafted type III anti-CEA humanized mouse monoclonal antibodies |
| 01/13/2004 | US6676909 Method for recovery of metals from metal-containing materials using medium temperature pressure leaching |
| 01/13/2004 | CA2280850C Quinazolinone-containing pharmaceutical compositions for prevention of neovascularization and for treating malignancies |
| 01/08/2004 | WO2004003562A2 Oncolytic viruses as phenotyping agents for neoplasms |
| 01/08/2004 | WO2004003545A1 Methods and compositions for inhibition of multi-drug resistance by hyaluronan oligomers |
| 01/08/2004 | WO2004003235A2 Probiotic strains, a process for the selection of them, compositions thereof, and their use |
| 01/08/2004 | WO2004003209A2 Nucleic acid isolated from the 5' non translated region (5'ntr) end of the human fgf-1 gene having ires activity |
| 01/08/2004 | WO2004003201A2 Antisense modulation of lrh1 expression |
| 01/08/2004 | WO2004003185A2 Plant deoxyribonucleoside kinase enzymes and their use |
| 01/08/2004 | WO2004003179A1 Differentiation modulating agents and uses therefor |
| 01/08/2004 | WO2004003174A2 Method of up-regulating tumor antigen expression using thymalfasin |
| 01/08/2004 | WO2004003166A2 Antibodies and uses thereof |
| 01/08/2004 | WO2004003164A2 Methods of organ regeneration |
| 01/08/2004 | WO2004003145A2 Compositions and methods for modulating physiology of epithelial junctional adhesion molecules for enhanced mucosal delivery of therapeutic compounds |
| 01/08/2004 | WO2004002998A1 Method for the separation of triglycoalkaloids |
| 01/08/2004 | WO2004002991A1 Porphyrin-polyamine conjugates for cancer therapy |
| 01/08/2004 | WO2004002965A1 Arylcarbonylpiperazines and heteroarylcarbonylpiperazines and the use thereof for treating benign and malignant tumour diseases |
| 01/08/2004 | WO2004002963A1 Amide derivative |
| 01/08/2004 | WO2004002961A1 Caspase inhibitors and uses thereof |
| 01/08/2004 | WO2004002960A1 Substituted quinoline ccr5 receptor antagonists |
| 01/08/2004 | WO2004002549A1 Use of organic compounds |
| 01/08/2004 | WO2004002535A1 Use of an npy y2 receptor antagonist for treating disorders related to angiogenesis |
| 01/08/2004 | WO2004002533A1 Stable liquid parenteral parecoxib formulation |
| 01/08/2004 | WO2004002528A1 Compositions and methods for therapeutic treatment |
| 01/08/2004 | WO2004002526A1 Co-administration of cg250 and il-2 or ifn-alpha for treating cancer such as renal cell carcinomas |
| 01/08/2004 | WO2004002514A1 Preventives/remedies for cancer |
| 01/08/2004 | WO2004002505A1 Compositions against inflammatory processes |
| 01/08/2004 | WO2004002497A1 Glycoalkaloid compositions and various uses thereof |
| 01/08/2004 | WO2004002485A1 Combination comprising a vasculostatic compound and an alkylating agent for the treatmemt of a tumor |
| 01/08/2004 | WO2004002484A1 Phosphodiesterase inhibitor |
| 01/08/2004 | WO2004002482A2 2-pyridin acetic acid derivatives with antiproliferative activity |
| 01/08/2004 | WO2004002477A1 2-(phenyl)-2h-pyrazole-3-carboxylic acid-n-4-(thioxo-heterocyclyl)-phenyl-amide derivatives and corresponding imino-heterocyclyl derivatives and relates compounds for use as inhibitors of the coagulation factors xa and/or viia for treating thromboses |
| 01/08/2004 | WO2004002476A2 Fluorinated chlorin and bacteriochlorin photosensitizers for photodynamic therapy |
| 01/08/2004 | WO2004002468A1 Method of producing a cationic liposomal preparation comprising a lipophilic compound |
| 01/08/2004 | WO2004002465A1 DRUG COMPOSITION CONTAINING NF-κB INHIBITOR |
| 01/08/2004 | WO2004002459A1 Hollow nanoparticle having modified cysteine residue and drug with the use thereof |
| 01/08/2004 | WO2004002455A1 Novel method of stabilizing diagnostic and therapeutic compounds in a cationic carrier system |
| 01/08/2004 | WO2004002454A1 Camptothecin-carboxylate formulations |
| 01/08/2004 | WO2004002431A2 Humanized anti-lymphotoyin beta receptor antibodies |
| 01/08/2004 | WO2004002424A2 Mammalian epo mimetic ch1 deleted mimetibodies, compositions, methods and uses |
| 01/08/2004 | WO2004002420A2 Oxime and/or hydrazone containing nitrosated and/or nitrosylated cyclooxigenase-2 selective inhibitors, compositions and methods of use |
| 01/08/2004 | WO2004002418A2 Compositions and methods comprising protein activated receptor antagonists |
| 01/08/2004 | WO2004002416A2 Methods and materials for treating human papillomavirus infections |
| 01/08/2004 | WO2004002367A1 Drug eluting stent |
| 01/08/2004 | WO2003095484A3 Polypeptides increasing p53 expression |
| 01/08/2004 | WO2003093455A3 Adenovirus vectors for immunotherapy |
| 01/08/2004 | WO2003090665A3 Regulation of erythrocyte apoptosis |
| 01/08/2004 | WO2003087174A3 Carbocyclic and oxacarbocyclic fumaric acid oligomers |
| 01/08/2004 | WO2003086315A3 Tyrosine kinase inhibitors |
| 01/08/2004 | WO2003086279A3 Inhibitors of akt activity |
| 01/08/2004 | WO2003085090A3 A human ribonucleotide reductase m2 subunit |
| 01/08/2004 | WO2003084928A8 Alpha, omega-dicarboximide derivatives as useful uro-selective α1α adrenoceptor blockers |
| 01/08/2004 | WO2003078614A3 Gntiii (udp-n-acethylglucosamine:beta-d mannoside beta (1,4)-n-acethylglucosaminy ltransferase iii) expression in plants |
| 01/08/2004 | WO2003076445A3 Microtubule stabilizing compounds |
| 01/08/2004 | WO2003076429A3 Azepane derivatives and their use as atk1 inhibitors |
| 01/08/2004 | WO2003075850A3 Methods for alzheimer's disease treatment and cognitive enhancement |
| 01/08/2004 | WO2003075844A3 Compositions and methods for preventing and treating cancer via modulating ube1l, isg15 and/or ubp43 |
| 01/08/2004 | WO2003070969A3 RNA INTERFERENCE MEDIATED INHIBITION OF BCL2 GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
| 01/08/2004 | WO2003070166A3 Novel tyloindicines and related processes, pharmaceutical compositions and methods |
| 01/08/2004 | WO2003067262A3 Methods and compositions involving the hsp90 activator aha1 |
| 01/08/2004 | WO2003066205A3 Microcapsules having high carotenoid content |
| 01/08/2004 | WO2003064378A3 Novel compounds that inhibit factor xa activity |
| 01/08/2004 | WO2003047618A3 Immunotherapeutic methods and systems |
| 01/08/2004 | WO2003030819A3 Tetracycline derivatives and methods of use thereof |
| 01/08/2004 | WO2003007890A3 Tropomyosin isoforms, and diagnostic and therapeutic uses therefor |
| 01/08/2004 | WO2003007800A3 Methods for diagnosing and treating diseases and conditions of the digestive system and cancer |
| 01/08/2004 | WO2002095067A3 INTERFERON α-14 POLYMORPHISM |
| 01/08/2004 | WO2002092623A8 INHIBITORS OF RECEPTOR ACTIVATOR OF NF-κB AND USES THEREOF |
| 01/08/2004 | WO2002092075A3 Therapeutic delivery of carbon monoxide |
| 01/08/2004 | WO2002091996A3 Methods for treating cancer |
| 01/08/2004 | WO2002083065A3 Peptide antiangiogenic drugs |
| 01/08/2004 | WO2002080952A3 Therapeutic use and identification of modulators of a hedgehog signalling pathway or one of its target pathways |
| 01/08/2004 | WO2002079448A3 G-protein coupled receptors |
| 01/08/2004 | WO2002072780A3 Igf antagonist peptides |
| 01/08/2004 | WO2002053596A3 Antibodies to insulin-like growth factor i receptor |
| 01/08/2004 | WO2002053522A3 Novel estrogen receptor ligands and methods i |
| 01/08/2004 | WO2002053130A3 Sustained release drug delivery devices with coated drug cores |
| 01/08/2004 | WO2002045737A3 Methods of treatment involving human mda-7 |
| 01/08/2004 | WO2001079524A3 Tissue-specific and pathogen-specific toxic agents, ribozymes, dnazymes and antisense oligonucleotides, and methods of use thereof |
| 01/08/2004 | WO2001066123A3 Composition consisting of phy906 and chemotherapeutic agents |